New developments in the treatment of peripheral T-cell lymphoma - role of Belinostat.

作者: Peter Reimer

DOI: 10.2147/CMAR.S85351

关键词: OncologyRefractoryBelinostatInternal medicinePeripheral T-cell lymphomaT-cell lymphomaConventional chemotherapyMedicineBioinformaticsChemotherapyAnaplastic lymphoma kinaseAnaplastic large-cell lymphoma

摘要: Peripheral T-cell lymphomas (PTCL) represent a heterogeneous group of rare malignancies that with the exception anaplastic lymphoma kinase expressing large cell lymphoma, share poor outcome after standard (eg, anthracycline-based) chemotherapy. Most patients are either refractory to initial therapy or eventually relapse. Randomized studies for relapsed/refractory PTCL not available, however, recently published data show conventional chemotherapy has very limited efficacy in salvage setting. Thus, novel drugs urgently needed improve this Belinostat, pan-histone deacetylase inhibitor, demonstrated meaningful and favorable toxicity profile two single-arm Phase II trials on 153 PTCL. The conclusive results led an accelerated approval by US Food Drug Administration. present review summarizes clinical available belinostat, its current role, future perspectives.

参考文章(47)
Marco Paulli, Mario Lazzarino, Fabio Menestrina, Leonardo Flenghi, Chris Wolf-Peeters, Pier Luigi Zinzani, Pier Giuseppe Pelicci, Brunangelo Falini, Vittorina Zagonel, Massimo F. Martelli, Antonino Carbone, Antonella Santucci, Giuseppe Todeschini, Stefano Pileri, Gregor Verhoef, Roberta Giardini, Marco Fizzotti, Iguacyra Araujo, Antonella Aiello, Hans Dieter Foss, ALK+ Lymphoma: Clinico-Pathological Findings and Outcome Blood. ,vol. 93, pp. 2697- 2706 ,(1999) , 10.1182/BLOOD.V93.8.2697
Randy D. Gascoyne, Patricia Aoun, Daniel Wu, Mukesh Chhanabhai, Brian F. Skinnider, Timothy C. Greiner, Stephan W. Morris, Joseph M. Connors, Julie M. Vose, David S. Viswanatha, Andrew Coldman, Dennis D. Weisenburger, Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma Blood. ,vol. 93, pp. 3913- 3921 ,(1999) , 10.1182/BLOOD.V93.11.3913.411K22_3913_3921
Christian Gisselbrecht, Dominique Cazals-Hatem, André Bosly, Bertrand Coiffier, Luc Xerri, Eric Lepage, Hervé Tilly, Josette Brière, Reda Bouhabdallah, Corinne Haioun, Jacques Diebold, Françoise Berger, Philippe Gaulard, Prognostic Significance of T-Cell Phenotype in Aggressive Non-Hodgkin's Lymphomas Blood. ,vol. 92, pp. 76- 82 ,(1998) , 10.1182/BLOOD.V92.1.76.413A19_76_82
S. Ascani, P.L. Zinzani, F. Gherlinzoni, E. Sabattini, A. Briskomatis, A. de Vivo, M. Piccioli, G. Fraternali Orcioni, F. Pieri, A. Goldoni, P.P. Piccaluga, D. Zallocco, R. Burnelli, L. Leoncini, B. Falini, S. Tura, S.A. Pileri, Peripheral T-cell lymphomas. Clinico-pathologic study of 168 cases diagnosed according to the R.E.A.L. Classification Annals of Oncology. ,vol. 8, pp. 583- 592 ,(1997) , 10.1023/A:1008200307625
Peter Gimsing, Mads Hansen, Lene M. Knudsen, P. Knoblauch, Ib Jarle Christensen, Chean Eng Ooi, Peter Buhl-Jensen, A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia European Journal of Haematology. ,vol. 81, pp. 170- 176 ,(2008) , 10.1111/J.1600-0609.2008.01102.X
U Lassen, LR Molife, M Sorensen, SA Engelholm, L Vidal, R Sinha, RT Penson, P Buhl-Jensen, E Crowley, Tjornelund, J, P Knoblauch, JS de Bono, A phase I study of the safety and pharmacokinetics of the histone deacetylase inhibitor belinostat administered in combination with carboplatin and/or paclitaxel in patients with solid tumours British Journal of Cancer. ,vol. 103, pp. 12- 17 ,(2010) , 10.1038/SJ.BJC.6605726
A Dodero, F Spina, F Narni, F Patriarca, I Cavattoni, F Benedetti, F Ciceri, D Baronciani, R Scimè, E Pogliani, A Rambaldi, F Bonifazi, S Dalto, B Bruno, P Corradini, Allogeneic transplantation following a reduced-intensity conditioning regimen in relapsed/refractory peripheral T-cell lymphomas: long-term remissions and response to donor lymphocyte infusions support the role of a graft-versus-lymphoma effect Leukemia. ,vol. 26, pp. 520- 526 ,(2012) , 10.1038/LEU.2011.240
Jennifer A. Kanakry, Yvette L. Kasamon, Christopher D. Gocke, Hua-Ling Tsai, Janice Davis-Sproul, Nilanjan Ghosh, Heather Symons, Javier Bolaños-Meade, Douglas E. Gladstone, Lode J. Swinnen, Leo Luznik, Ephraim J. Fuchs, Richard J. Jones, Richard F. Ambinder, Outcomes of related donor HLA-identical or HLA-haploidentical allogeneic blood or marrow transplantation for peripheral T cell lymphoma. Biology of Blood and Marrow Transplantation. ,vol. 19, pp. 602- 606 ,(2013) , 10.1016/J.BBMT.2013.01.006
P Corradini, C Tarella, F Zallio, A Dodero, M Zanni, P Valagussa, A M Gianni, A Rambaldi, T Barbui, S Cortelazzo, Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation. Leukemia. ,vol. 20, pp. 1533- 1538 ,(2006) , 10.1038/SJ.LEU.2404306